/ Lupin Launches Generic Version Of Ortho-Cyclen 28 Tablets In The US ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Tuesday, 24 January 2017

Lupin Limited, a pharmaceutical company announced on Tuesday that it has launched its Norgestimate and Ethinyl Estradiol Tablets USP, 0.25 mg/0.035 mg and have received approval from the United States Food and Drug Administration (FDA) earlier to market a generic version of Janssen Pharmaceutical Inc.’s Ortho-Cyclen 28 Tablets (Norgestimate/Ethinyl Estradiol).

The tablets launched by the company are an AB rated generic equivalent of Janssen Pharmaceuticals Inc.’s Ortho-Cyclen 28 Tablets (Norgestimate/Ethinyl Estradiol), which had sales of USD 204 million (IMS MAT September 2016).

Lupin delivers a wide range of branded & generic formulations, biotechnology products and APIs globally. The company plays a major role in cardiovascular, diabetology, asthma, pediatric, CNS, GI, Anti-Infective and in the NSAID space and holds a global leadership position in the Anti-TB segment.

Lupin Ltd is currently trading at Rs 1497, up by Rs 14.5 or 0.98% from its previous closing of Rs 1482.5 on the BSE. The scrip opened at Rs 1489 and has touched a high and low of Rs 1501 and Rs 1480.45 respectively. So far 327820(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 66932.77 crore.

The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 1911.55 on 09-Feb-2016 and a 52 week low of Rs 1294.05 on 29-Mar-2016. Last one week high and low of the scrip stood at Rs 1509.8 and Rs 1450.75 respectively.

The promoters holding in the company stood at 46.71 % while Institutions and Non-Institutions held 41.46 % and 11.83 % respectively. The stock is currently trading above its 200 DMA.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717